CBiPES

CBiPES
Clinical data
ATC code	none;
Identifiers
	IUPAC name N-(4'-cyano-[1,1'-biphenyl]-3-yl-N-(3-pyridinylmethyl)ethanesulfonamide;
CAS Number	856702-40-4 ;
PubChem CID	9864510;
IUPHAR/BPS	3372;
ChemSpider	8040202;
CompTox Dashboard (EPA)	DTXSID70432071 ;
Chemical and physical data
Formula	C21H19N3O2S
Molar mass	377.459 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES N#Cc1ccc(cc1)-c(ccc2)cc2N(S(=O)(=O)CC)Cc3cccnc3;
	InChI InChI=1S/C21H19N3O2S/c1-2-27(25,26)24(16-18-5-4-12-23-15-18)21-7-3-6-20(13-21)19-10-8-17(14-22)9-11-19/h3-13,15H,2,16H2,1H3; Key:HDVYXILCBYGKGU-UHFFFAOYSA-N;

CBiPES is a drug used in scientific research that acts as a selective positive allosteric modulator for the metabotropic glutamate receptor group II subtype mGluR₂. It has potentially antipsychotic effects in animal models, and is used for researching the role of mGluR₂ receptors in schizophrenia and related disorders.[1][2][3]

References

Johnson, M. P.; Barda, D.; Britton, T. C.; Emkey, R.; Hornback, W. J.; Jagdmann, G. E.; McKinzie, D. L.; Nisenbaum, E. S.; Tizzano, J. P.; Schoepp, D. D. (2005). "Metabotropic glutamate 2 receptor potentiators: Receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)". Psychopharmacology. 179 (1): 271–283. doi:10.1007/s00213-004-2099-9. PMID 15717213.
Fell, M. J.; Katner, J. S.; Johnson, B. G.; Khilevich, A.; Schkeryantz, J. M.; Perry, K. W.; Svensson, K. A. (2010). "Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge". Neuropharmacology. 58 (3): 632–639. doi:10.1016/j.neuropharm.2009.11.014. PMID 19951716.
Sanger, H.; Hanna, L.; Colvin, E. M.; Grubisha, O.; Ursu, D.; Heinz, B. A.; Findlay, J. D.; Vivier, R. G.; Sher, E.; Lodge, D.; Monn, J. A.; Broad, L. M. (2012). "Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR". Neuropharmacology. 66: 264–273. doi:10.1016/j.neuropharm.2012.05.023. PMID 22659090.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Johnson, M. P.; Barda, D.; Britton, T. C.; Emkey, R.; Hornback, W. J.; Jagdmann, G. E.; McKinzie, D. L.; Nisenbaum, E. S.; Tizzano, J. P.; Schoepp, D. D. (2005). "Metabotropic glutamate 2 receptor potentiators: Receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)". Psychopharmacology. 179 (1): 271–283. doi:10.1007/s00213-004-2099-9. PMID 15717213.

[2] Fell, M. J.; Katner, J. S.; Johnson, B. G.; Khilevich, A.; Schkeryantz, J. M.; Perry, K. W.; Svensson, K. A. (2010). "Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge". Neuropharmacology. 58 (3): 632–639. doi:10.1016/j.neuropharm.2009.11.014. PMID 19951716.

[3] Sanger, H.; Hanna, L.; Colvin, E. M.; Grubisha, O.; Ursu, D.; Heinz, B. A.; Findlay, J. D.; Vivier, R. G.; Sher, E.; Lodge, D.; Monn, J. A.; Broad, L. M. (2012). "Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR". Neuropharmacology. 66: 264–273. doi:10.1016/j.neuropharm.2012.05.023. PMID 22659090.